Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction)
>50% reduction in inhaled steroid usage 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to higher >50% reduction in inhaled steroid usage 28 to 32 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
1 finding from 1 review
- OR 2.5 [2.02, 3.1]4 studies · 1634 participantsModerate